These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 21254662)

  • 21. Torcetrapib impairs endothelial function in hypertension.
    Simic B; Hermann M; Shaw SG; Bigler L; Stalder U; Dörries C; Besler C; Lüscher TF; Ruschitzka F
    Eur Heart J; 2012 Jul; 33(13):1615-24. PubMed ID: 21920972
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effect of L-carnitine and propionyl-L-carnitine on endothelial function of small mesenteric arteries from SHR.
    Alvarez de Sotomayor M; Bueno R; Pérez-Guerrero C; Herrera MD
    J Vasc Res; 2007; 44(5):354-64. PubMed ID: 17483601
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Adaptor protein p66(Shc) mediates hypertension-associated, cyclic stretch-dependent, endothelial damage.
    Spescha RD; Glanzmann M; Simic B; Witassek F; Keller S; Akhmedov A; Tanner FC; Lüscher TF; Camici GG
    Hypertension; 2014 Aug; 64(2):347-53. PubMed ID: 24842918
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Amlodipine ameliorates endothelial dysfunction in mesenteric arteries from spontaneously hypertensive rats.
    He X; Zhang HL; Zhao M; Yang JL; Cheng G; Sun L; Li DL; Jiang HK; Zhao Q; Yu XJ; Zang WJ
    Clin Exp Pharmacol Physiol; 2011 Apr; 38(4):255-61. PubMed ID: 21306413
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Exercise training improves aortic endothelium-dependent vasorelaxation and determinants of nitric oxide bioavailability in spontaneously hypertensive rats.
    Graham DA; Rush JW
    J Appl Physiol (1985); 2004 Jun; 96(6):2088-96. PubMed ID: 14752124
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Atorvastatin enhanced nitric oxide release and reduced blood pressure, nitroxidative stress and rantes levels in hypertensive rats with diabetes.
    Mason RP; Corbalan JJ; Jacob RF; Dawoud H; Malinski T
    J Physiol Pharmacol; 2015 Feb; 66(1):65-72. PubMed ID: 25716966
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Endothelial regulation of cyclic GMP and vascular responses in hypertension.
    Shirasaki Y; Kolm P; Nickols GA; Lee TJ
    J Pharmacol Exp Ther; 1988 Apr; 245(1):53-8. PubMed ID: 2834546
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Hypercholesterolemia does not alter endothelial function in spontaneously hypertensive rats.
    Lorkowska B; Bartus M; Franczyk M; Kostogrys RB; Jawien J; Pisulewski PM; Chlopicki S
    J Pharmacol Exp Ther; 2006 Jun; 317(3):1019-26. PubMed ID: 16547168
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Role of endothelium and nitric oxide in experimental hypertension.
    Vapaatalo H; Mervaala E; Nurminen ML
    Physiol Res; 2000; 49(1):1-10. PubMed ID: 10805399
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Human endothelial dysfunction: EDRFs.
    Flammer AJ; Lüscher TF
    Pflugers Arch; 2010 May; 459(6):1005-13. PubMed ID: 20383717
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Contribution of oxidative stress to endothelial dysfunction in hypertension.
    Silva BR; Pernomian L; Bendhack LM
    Front Physiol; 2012; 3():441. PubMed ID: 23227009
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Endothelial dysfunction: a multifaceted disorder (The Wiggers Award Lecture).
    Félétou M; Vanhoutte PM
    Am J Physiol Heart Circ Physiol; 2006 Sep; 291(3):H985-1002. PubMed ID: 16632549
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A critical review of the role of endothelial factors in the pathogenesis of hypertension.
    Schiffrin EL
    J Cardiovasc Pharmacol; 2001 Nov; 38 Suppl 2():S3-6. PubMed ID: 11811373
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Mechanisms of endothelial dysfunction: clinical significance and preventive non-pharmacological therapeutic strategies.
    Taddei S; Ghiadoni L; Virdis A; Versari D; Salvetti A
    Curr Pharm Des; 2003; 9(29):2385-402. PubMed ID: 14529554
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Endothelial dysfunction in diabetes: multiple targets for treatment.
    Ding H; Triggle CR
    Pflugers Arch; 2010 May; 459(6):977-94. PubMed ID: 20238124
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Endothelial Dysfunction in Resistance Arteries of Hypertensive Humans: Old and New Conspirators.
    Virdis A; Taddei S
    J Cardiovasc Pharmacol; 2016 Jun; 67(6):451-7. PubMed ID: 26808712
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Venous endothelial function in cardiovascular disease.
    Dardi P; Dos Reis Costa DEF; Assunção HCR; Rossoni LV
    Biosci Rep; 2022 Nov; 42(11):. PubMed ID: 36281946
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Endothelial dysfunction: a strategic target in the treatment of hypertension?
    Tang EH; Vanhoutte PM
    Pflugers Arch; 2010 May; 459(6):995-1004. PubMed ID: 20127126
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Heterogeneity of endothelial dysfunction in hypertension.
    Lüscher TF
    Eur Heart J; 1992 Sep; 13 Suppl D():50-5. PubMed ID: 1396860
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pathogenic Mechanisms of Pulmonary Arterial Hypertension: Homeostasis Imbalance of Endothelium-Derived Relaxing and Contracting Factors.
    Zhu J; Yang L; Jia Y; Balistrieri A; Fraidenburg DR; Wang J; Tang H; Yuan JX
    JACC Asia; 2022 Dec; 2(7):787-802. PubMed ID: 36713766
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.